Skip to main content
Market icon
Teknologi·Drug

FDA menyetujui Retatrutide tahun ini?

Market icon
Teknologi·Drug

FDA menyetujui Retatrutide tahun ini?

16% peluang
Polymarket

$560,874 Vol.

16% peluang
Polymarket

$560,874 Vol.

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.Trader consensus prices "No" FDA approval of retatrutide—a triple-hormone receptor agonist (GLP-1/GIP/glucagon) from Eli Lilly—at an 84.5% implied probability for 2026, driven by the absence of a New Drug Application (NDA) submission amid an expansive Phase 3 program. Positive topline results from the TRANSCEND-T2D-1 trial, released March 19, 2026, demonstrated A1C reductions of up to 2.0% and 16.8% average weight loss at 40 weeks in type 2 diabetes patients, building on TRIUMPH-4's up to 28.7% weight reduction in obesity with knee osteoarthritis from December 2025. However, multiple TRIUMPH and TRANSCEND trials remain active through mid-2026 or later, with NDA filing projected for late 2026 and standard FDA review of about 10 months pushing approval into 2027. Upcoming readouts could refine timelines, though regulatory uncertainties persist.

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Volume
$560,874
Tanggal Berakhir
Dec 31, 2026
Pasar Dibuka
Jan 12, 2026, 5:52 PM ET

Resolver

0x65070BE91...
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.Trader consensus prices "No" FDA approval of retatrutide—a triple-hormone receptor agonist (GLP-1/GIP/glucagon) from Eli Lilly—at an 84.5% implied probability for 2026, driven by the absence of a New Drug Application (NDA) submission amid an expansive Phase 3 program. Positive topline results from the TRANSCEND-T2D-1 trial, released March 19, 2026, demonstrated A1C reductions of up to 2.0% and 16.8% average weight loss at 40 weeks in type 2 diabetes patients, building on TRIUMPH-4's up to 28.7% weight reduction in obesity with knee osteoarthritis from December 2025. However, multiple TRIUMPH and TRANSCEND trials remain active through mid-2026 or later, with NDA filing projected for late 2026 and standard FDA review of about 10 months pushing approval into 2027. Upcoming readouts could refine timelines, though regulatory uncertainties persist.

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:
For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)
For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced
For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)
For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:
Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:
Approvable letters that require additional actions before approval
Tentative approvals pending patent or exclusivity expiration
FDA requests for additional information or studies
Extension of Prescription Drug User Fee Amendments dates
Approval for compassionate use or expanded access programs only
Approval only for export or for use outside the United States
Emergency Use Authorization (EUA) without full approval
Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Volume
$560,874
Tanggal Berakhir
Dec 31, 2026
Pasar Dibuka
Jan 12, 2026, 5:52 PM ET

Resolver

0x65070BE91...
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

Hati-hati dengan link eksternal.

Pertanyaan yang Sering Diajukan

"FDA menyetujui Retatrutide tahun ini?" adalah pasar prediksi di Polymarket di mana trader membeli dan menjual saham "Ya" atau "Tidak" berdasarkan apakah mereka yakin event ini akan terjadi. Probabilitas crowd-sourced saat ini adalah 16% untuk "Yes." Misalnya, jika "Ya" dihargai 16¢, pasar secara kolektif memberikan peluang 16% bahwa event ini akan terjadi. Peluang ini bergeser terus-menerus saat trader bereaksi terhadap perkembangan dan informasi baru. Saham dengan hasil yang benar bisa ditukarkan seharga $1 setiap saham saat pasar diselesaikan.

Per hari ini, "FDA menyetujui Retatrutide tahun ini?" telah menghasilkan $560.9K dalam total volume trading sejak pasar diluncurkan pada Jan 12, 2026. Tingkat aktivitas trading ini mencerminkan keterlibatan kuat dari komunitas Polymarket dan membantu memastikan bahwa peluang saat ini diinformasikan oleh kumpulan besar peserta pasar. Kamu bisa melacak pergerakan harga langsung dan trading di hasil apa pun langsung di halaman ini.

Untuk trading di "FDA menyetujui Retatrutide tahun ini?," cukup pilih apakah kamu yakin jawabannya "Ya" atau "Tidak." Setiap sisi memiliki harga saat ini yang mencerminkan probabilitas tersirat pasar. Masukkan jumlah kamu dan klik "Trade." Jika kamu membeli saham "Ya" dan hasilnya diselesaikan sebagai "Ya," setiap saham membayar $1. Jika diselesaikan sebagai "Tidak," saham "Ya" kamu bernilai $0. Kamu juga bisa menjual sahammu kapan saja sebelum resolusi jika kamu ingin mengamankan keuntungan atau memotong kerugian.

Probabilitas saat ini untuk "FDA menyetujui Retatrutide tahun ini?" adalah 16% untuk "Yes." Ini berarti keramaian Polymarket saat ini percaya ada peluang 16% bahwa event ini akan terjadi. Peluang ini diperbarui secara real-time berdasarkan trade aktual, memberikan sinyal yang terus diperbarui tentang apa yang diharapkan pasar.

Aturan resolusi untuk "FDA menyetujui Retatrutide tahun ini?" mendefinisikan dengan tepat apa yang harus terjadi agar setiap hasil dinyatakan sebagai pemenang — termasuk sumber data resmi yang digunakan untuk menentukan hasilnya. Kamu bisa meninjau kriteria resolusi lengkap di bagian "Aturan" di halaman ini di atas komentar. Kami menyarankan membaca aturan dengan cermat sebelum trading, karena mereka menentukan kondisi tepat, kasus khusus, dan sumber yang mengatur bagaimana pasar ini diselesaikan.